Table 4 Sex and country representation in the authorship of evidence supporting the 2021 SSC recommendations
Recommendation | First Author Sex: n (%) | First Author Country Income* n (%) | First Author Country Region** n (%) | Last Author Sex, n (%) | Last Author Country Income, n (%) | Last Author Country Region, n (%) |
|---|---|---|---|---|---|---|
Screening and Early Treatment (n = 30) | Males: 24 (80%) Females: 5 (17%) Unknown: 1 (3%) | High: 23 (77%) UM: 3 (10%) LM: 1 (3%) Low: 3 (10%) | EAP: 1 (3%) ECA: 8 (27%) LAC: 5 (17%) MENA: 0 (0%) NA: 13 (43%) SA: 0 (0%) SSA: 3 (10%) | Males: 23 (77%) Females: 7 (23%) | High: 26 (87%) UM: 3 (10%) LM: 0 (0%) Low: 1 (3%) | EAP: 0 (0%) ECA: 12 (40%) MENA: 0 (0%) NA: 13 (43%) SA: 0 (0%) SSA: 1 (3%) LAC: 4 (14%) |
Infection (n = 126) | Males: 84 (67%) Females: 29 (23%) Unknown: 13 (10%) | High: 116 (92%) UM: 6 (5%) LM: 2 (2%) Low: 2 (2%) | EAP: 22 (17%) ECA: 47 (37%) LAC: 5 (4%) MENA: 4 (3%) NA: 46 (37%) SA: 0 (0%) SSA: 2 (2%) | Males: 94 (75%) Females: 20 (16%) Unknown: 12 (9%) | High: 118 (94%) UM: 4 (3%) LM: 1 (1%) Low: 0 (0%) Unknown: 3 (2%) | EAP: 17 (14%) ECA: 47 (37%) LAC: 4 (3%) MENA: 4 (3%) NA: 51 (41%) SA: 0 (0%) SSA: 0 (0%) Unknown: 3 (2%) |
Hemodynamic Management (n = 47) | Males :39 (83%) Females: 7 (15%) Unknown: 1 (2%) | High: 41 (87%) UM: 2 (4%) LM: 3 (7%) Low: 1 (2%) | EAP: 5 (11%) ECA: 13 (28%) LAC: 2 (4%) MENA: 1 (2%) NA: 23 (49%) SA: 1 (2%) SSA: 2 (4%) | Males: 34 (72%) Females: 10 (21%) Unknown: 3 (7%) | High: 42 (89%) UM: 2 (4%) LM: 3 (7%) Low: 0 (0%) | EAP: 5 (11%) ECA: 13 (28%) LAC: 2 (4%) MENA: 1 (2%) NA: 24 (51%) SA: 1 (2%) SSA: 1 (2%) |
Ventilation (n = 41) | Males: 36 (88%) Females: 5 (12%) | High: 36 (88%) UM: 5 (12%) LM: 0 (0%) Low: 0 (0%) | EAP: 1 (2%) ECA: 17 (42%) LAC: 5 (12%) MENA: 0 (0%) NA: 18 (44%) SA: 0 (0%) SSA: 0 (0%) | Males: 38 (93%) Females: 2 (5%) Unknown: 1 (2%) | High: 36 (88%) UM: 4 (10%) LM: 0 (0%) Low: 0 (0%) Unknown: 1 (2%) | EAP: 0 (0%) ECA: 21 (51%) LAC: 4 (10%) MENA: 0 (0%) NA: 15 (37%) SA: 0 (0%) SSA: 0 (0%) Unknown: 1 (2%) |
Additional therapies (n = 36) | Males: 29 (81%) Females: 7 (19%) | High: 33 (92%) UM: 1 (3%) LM: 2 (5%) Low: 0 (0%) | EAP: 4 (11%) ECA: 17 (47%) MENA: 1 (3%) NA: 11 (30%) SA: 2 (6%) SSA: 0 (0%) LAC: 1 (3%) | Males: 29 (80%) Females: 6 (17%) Unknown: 1 (3%) | High: 33 (92%) UM: 1 (3%) LM: 2 (5%) Low: 0 (0%) | EAP: 2 (6%) ECA: 18 (50%) MENA: 1 (3%) NA: 12 (33%) SA: 2 (6%) SSA: 0 (0%) LAC: 1 (3%) |
Long-term Outcomes/ Goals of Care (n = 83) | Males: 46 (55%) Females: 35 (42%) Unknown: 2 (3%) | High: 82 (99%) UM: 1 (1%) LM: 0 (0%) Low: 0 (0%) | EAP: 7 (8%) ECA: 30 (36%) MENA: 0 (0%) LAC: 0 (0%) NA: 46 (55%) SA: 0 (0%) SSA: 0 (0%) | Males: 46 (55%) Females: 35 (42%) Unknown: 2 (3%) | High: 82 (99%) UM: 1 (1%) LM: 0 (0%) Low: 0 (0%) | EAP: 7 (8%) ECA: 30 (36%) MENA: 0 (0%) LAC: 0 (0%) NA: 46 (55%) SA: 0 (0%) SSA: 0 (0%) |